knowledge -WSS

knowledge

author：leisure time 2025-09-02 11:48:19 - browse：4

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

focus

WSS

Congress may force more Covid

PEPFAR is under serious threat — and so is global health

White House touts steps to stem shortages of cancer treatments

Long Covid needs a new name — and a new frame

Medicare Advantage enrollment hits roughly 33.4 million

As AI regulations shape up, health tech startups beg for clarity

entertainment

knowledge

focus

In age of alternative facts, a scholarly course on calling out crap

Acelyrin, a rare IPO success, stumbles in its first big test

Walensky prepares to leave CDC — and Congress — behind

Pig kidney works a record two months in donated body

Dobbs anniversary: the lost opportunity of abortion as health care

Hospitals consider fixing cancer drug shortages on their own

After affirmative action ruling, medical educators look to 'holistic review'

Regeneron agrees to White House price limits on anti

Wildfire smoke exposes gaps in outdoor worker protections

Long Covid needs a new name — and a new frame

explore

IRA could hurt research into orphan drugs for rare diseases

FDA approves updated Covid vaccines

Researchers tackle phage therapy hurdles for wider adoption

Regeneron agrees to White House price limits on anti

Walmart eyes Medicare Advantage provider ChenMed

FDA panel endorses Alnylam’s heart drug — after picking it apart

Wikipedia

Wikipedia

focus

explore